NDAINHALATIONGAS
Approved
Sep 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
OXYGEN, USP (oxygen) by Universal Cells. Approved for hypoxemia, copd, hypoxia. First approved in 2013.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYGEN, USP is a pharmaceutical-grade gaseous oxygen product administered via inhalation to treat hypoxemia, COPD, and hypoxia. It functions as a therapeutic gas that directly increases oxygen availability in the bloodstream and tissues. This is a foundational respiratory therapy used across acute and chronic care settings.
Peak
Peak lifecycle positioning indicates stable market presence with mature sales infrastructure, though limited growth upside suggests smaller brand team footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on OXYGEN, USP at Universal Cells? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.